지혈 제품 시장 규모 : 제품별, 용도별, 최종 용도별 - 세계 예측(-2032년)

Global Hemostasis Products Market will expand at a notable CAGR between 2023 and 2032, driven by the growing incidence of accidents and trauma cases across the globe. According to the ILO, approximately 2.3 million men and women globally lose their lives due to work-related accidents or illnesses each year, equating to more than 6,000 daily fatalities. Each year, the world witnesses roughly 340 million occupational accidents. Hemostasis products, such as clotting factors and hemostatic agents, are critical for controlling bleeding in emergencies. With a rise in accidents and traumatic injuries, the demand for these products is on the upswing, as they are essential for saving lives and preventing excessive bleeding, contributing to the market's expansion.

The overall hemostasis products market is segregated based on product, application, end-use, and region.

Infusible hemostasis products industry will register significant growth throughout 2023-2032. Infusible hemostasis products are in high demand due to their effectiveness in rapidly controlling bleeding in various medical procedures and trauma situations. These products, such as clotting factors and hemostatic agents, offer a critical solution for minimizing blood loss, reducing the risk of complications, and improving patient outcomes. With an increasing number of surgeries, trauma cases, and medical interventions, the demand for infusible hemostasis products continues to rise, driving market growth.

The hemophilia segment could accumulate a notable hemostasis products market share by 2032. Hemostasis products are increasingly utilized for hemophilia treatment due to their vital role in managing this bleeding disorder. Hemophilia patients lack essential clotting factors, and hemostasis products, including factor concentrates and clotting factor replacement therapies, help control and prevent excessive bleeding. With improved diagnosis, treatment access, and patient care, the demand for these products in the management of hemophilia is on the rise, contributing to their increased utilization in this medical field.

Europe hemostasis products industry is expanding at a noticeable pace due to several factors. The region's aging population, with a higher prevalence of conditions requiring hemostasis intervention, contributes to market growth. Advances in medical technology and surgical procedures increase the demand for these products. Additionally, stringent healthcare regulations and rising awareness of hemostasis therapies promote their use. These combined factors create a conducive environment for the industry's expansion in Europe.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & workings
• 1.3 Forecast calculations
• 1.4 Data Sources
  • 1.4.1 Primary
  • 1.4.2 Secondary
    • 1.4.2.1 Paid sources
    • 1.4.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Global hemostasis products market 360 degree synopsis, 2018 - 2032
• 2.2 Regional trends
• 2.3 Product trends
• 2.4 Application trends
• 2.5 End-use trends

Chapter 3 Hemostasis Products Industry Insights

• 3.1 COVID- 19 impact analysis
• 3.2 Industry ecosystem analysis
• 3.3 Technology landscape
• 3.4 Regulatory landscape
• 3.5 Industry impact forces
  • 3.5.1 Growth drivers
    • 3.5.1.1 The rising prevalence of cardiac disorders worldwide
    • 3.5.1.2 The growing incidence of accidents and trauma cases across the globe
    • 3.5.1.3 Technological advancements in hemostasis products
  • 3.5.2 Industry pitfalls & challenges
    • 3.5.2.1 High expense needed for hemostasis products due to the usage of advanced technology for hemostat
    • 3.5.2.2 Lack of skilled professionals for carrying out surgical procedures
• 3.6 Growth potential analysis
  • 3.6.1 By product
  • 3.6.2 By application
  • 3.6.3 By end-use
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
  • 4.1.1 Medtronic Plc
  • 4.1.2 Johnson & Johnson Services Inc
  • 4.1.3 Baxter International Inc
• 4.2 Competitive analysis of major market players, 2022
• 4.3 Competitive positioning matrix, 2022
• 4.4 Strategic outlook matrix, 2022

Chapter 5 Hemostasis Products Market Estimates and Forecast, By Product (Revenue)

• 5.1 Key trends, by product
• 5.2 Topical hemostasis products
  • 5.2.1 Gelatin
  • 5.2.2 Polysaccharides
  • 5.2.3 Oxidized regenerated cellulose
  • 5.2.4 Collagen
• 5.3 Infusible hemostasis products
  • 5.3.1 Fresh frozen plasma (FFP)
  • 5.3.2 Factor VIII
  • 5.3.3 Platelet concentrate from donor blood
  • 5.3.4 Prothrombin
• 5.4 Advanced hemostasis products
  • 5.4.1 Flowable
  • 5.4.2 Thrombin
  • 5.4.3 Synthetic sealant
  • 5.4.4 Fibrin

Chapter 6 Hemostasis Products Market Estimates and Forecast, By Application (Revenue)

• 6.1 Key trends, by application
• 6.2 Trauma
• 6.3 Surgery
• 6.4 Hemophilia
• 6.5 Myocardial infarction
• 6.6 Others

Chapter 7 Hemostasis Products Market Estimates and Forecast, By End-use (Revenue)

• 7.1 Key trends, by end-use
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers
• 7.4 Others

Chapter 8 Hemostasis Products Market Estimates and Forecast, By Region (Revenue)

• 8.1 Key trends, by region
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Switerland
  • 8.3.7 The Netherlands
  • 8.3.8 Denmark
  • 8.3.9 Poland
  • 8.3.10 Sweden
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 New Zealand
  • 8.4.7 Thailand
  • 8.4.8 Vietnam
  • 8.4.9 Indonesia
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Colombia
  • 8.5.5 Chile
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Turkey

Chapter 9 Company Profiles

• 9.1 Medtronic Plc
• 9.2 Johnson & Johnson Services Inc
• 9.3 Baxter International Inc
• 9.4 Pfizer, Inc
• 9.5 Becton, Dickinson and Company (BD)
• 9.6 B. Braun Melsungen AG
• 9.7 Tricol Biomedical
• 9.8 Hemostasis LLC
• 9.9 Teleflex Incorporated
• 9.10 CuraMedical BV